Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 141,200 shares, a growth of 27.7% from the December 15th total of 110,600 shares. Based on an average daily volume of 95,500 shares, the short-interest ratio is presently 1.5 days. Currently, 0.7% of the shares of the stock are short sold.

Institutional Trading of Aileron Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ALRN. KG&L Capital Management LLC acquired a new position in shares of Aileron Therapeutics during the 3rd quarter valued at about $46,000. Sigma Planning Corp boosted its holdings in Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after purchasing an additional 86,185 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after purchasing an additional 59,370 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after buying an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics during the 2nd quarter worth approximately $4,925,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Price Performance

Aileron Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $7.42. The firm has a 50 day moving average of $2.52 and a 200 day moving average of $2.80.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).